Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06721273

Iodine Supplementation and Fertility Parameters

Iodine has been identified as a potential factor influencing female fertility during the childbearing years. The American Thyroid Association recommends that women attempting to conceive take a supplement containing 150 µg of iodine. However, no clinical trials have specifically examined the necessity of iodine supplementation in women experiencing infertility. Furthermore, no information is available on the optimal dose and duration of iodine supplementation to increase the chances of successful treatment in this group of women. Therefore, this study aims to investigate the effects of iodine supplementation on fertility parameters in infertile women.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

This double-blind randomized clinical trial will be conducted in infertility clinic on women with diminished ovarian reserve and undergoing in vitro fertilization (IVF) cycle treatment. According to the Bologna criteria, decreased ovarian reserve is defined as having 3 to 5 antral follicles and an anti-Müllerian hormone concentration ranging from 0.1 to 1.5 ng/ml. All women diagnosed with diminished ovarian reserve who meet the inclusion and exclusion criteria outlined in the general information section of the clinical trial and have provided written consent to participate will be examined. Following enrollment and baseline measurements, women will be randomly assigned to treatment groups-placebo and iodine supplement (150 µg/day of iodine)-in a 1:1 allocation ratio, using a random number table. In the intervention group, women will take 150 µg of iodine daily (one tablet per day, Tavan Institute, Tehran, Iran) for two months prior to starting the new IVF cycle. In the control group, participants will take a placebo tablet daily (containing white wheat flour, designed to match the size, shape, and color of the iodine tablet, Tavan Institute, Tehran, Iran) for the same duration before beginning the new IVF cycle. Women of two groups will be followed until the end of IVF cycle. Women in both groups will be monitored until the completion of the IVF cycle. Throughout the study, the following parameters will be assessed based on the timeline of the IVF cycle: the number of retrieved oocytes, the number of mature (MII) oocytes, the number of embryos, embryo quality, biochemical pregnancy, and clinical pregnancy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with diminished ovarian reserve
  • Willingness to participate
  • Age range: 18 to 45 years
  • Women with a menstrual cycle of 21 to 42 days
  • Women who have not used any contraceptive methods in the past 12 months
  • Women who have not had in sexual intercourse for more than 2 months

Exclusion criteria

  • Unwillingness to participate
  • Women with polycystic ovary syndrome or endometriosis
  • Diagnosis of any thyroid disease
  • Use of any medication that affects the thyroid function
  • Use of dietary supplements containing iodine (excluding those considered in the present study)
  • Use of iodine-containing disinfectants

Treatment and study plan

Iodine

Dietary Supplement

In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.

Placebo

Dietary Supplement

Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.

Primary outcomes

  1. Number of retrieved oocytes

    Time frame: 2 weeks after the start of ovarian stimulation (approximately 2 months after intervention)

    Total count of mature eggs (oocytes) collected from a woman's ovaries during an IVF cycle through the egg retrieval procedure by embryologists

  2. Number of mature (MII) oocytes

    Time frame: 2 weeks after the start of ovarian stimulation (approximately 2 months after intervention)

    Total count of oocytes that have reached the metaphase II stage of meiosis. This measurement is done by embryologists

Secondary outcomes

  1. Number of embryos

    Time frame: 16-18 hours after insemination

    Number of fertilized eggs (oocytes) that develop into embryos after the fertilization process with sperm

  2. Quality of embryos

    Time frame: 3 days after fertilization

    Quality of embryos is graded by embryologists using 3-point score scale

  3. Biochemical pregnancy

    Time frame: 12 days after embryo transfer

    Biochemical pregnancy is confirmed by βHCG test

  4. Clinical pregnancy

    Time frame: 3 weeks after embryo transfer

    Presence of one or more gestational sacs during transvaginal scans

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Pantea Nazeri, Associate Professor

CONTACT

[email protected]/[email protected]

+98 21 61192357

Sponsors and collaborators

Lead sponsor

Tehran University of Medical Sciences

Other

Registry information

Official study title

The Effect of Iodine Supplementation on Fertility Parameters in Women Experiencing Infertility

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 6, 2024
Registry last updated
Dec 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.